Qiming Venture Partners: Technology and Healthcare Investment

What we found

The funds

As of 2017, Qiming Venture Partners managed $550M in assets. The firm has raised three new funds totaling $1.39 Billion, which includes a USD Fund VI of $935 million, an RMB Fund V of 2.1 billion, and a U.S. Healthcare Fund I of $120 million. In 2006, the firm reported eleven US Dollar funds and seven RMB funds with a combined size of $9.5 billion. By 2022, the latest funds reached $3.2b. The firm also cites a total of $4 billion in managed assets. According to shizune.co, founders raised 500M USD, while the Qiming Venture Partners USA fund size is listed as 48,091. The platform notes 28,219 investors in the relevant industry, stage, and region. [1] [2] [3] [4] [5]

Portfolio outcomes

Qiming Venture Partners manages a portfolio of 210 companies. One notable outcome is LanzaTech, which had a market capitalization of $2 billion at its initial public offering. The share price for LanzaTech at the time of the IPO was $10.00. Another portfolio company, HyperStrong, experienced a significant increase from its issue price, reaching a gain of 229.21%. [13] [14]

The firm

Qiming Venture Partners was established in 2006. The firm focuses on early to growth-stage investments in the healthcare and Technology, Media and Telecom (TMT) sectors. It targets companies with high growth potential and the ability to disrupt existing markets or create new ones. The firm supports companies throughout their lifecycle, from seed stage to growth equity. Its investment areas include artificial intelligence, robotics, semiconductors, enterprise software, internet and consumer businesses, as well as pharmaceuticals and healthcare services. Qiming Venture Partners maintains a presence in key innovation hubs and leverages its Hong Kong office for international collaborations and capital raising. The firm states that it is committed to finding great companies for the future and bringing long-term value to societies. Its investment team spends significant time researching industry trends, technology developments, and changes in consumer habits. The firm makes comprehensive contact with entrepreneurs, using a deep understanding of business operations and scientific research data to grasp investment opportunities and assess risks. A key component of its strategy is focus, aiming to have good insights and rich contacts for the industries it cares about. This approach allows the firm to truly understand the projects it invests in, provide help after investment, and form an ecosystem within its portfolio companies. Qiming Venture Partners has a reputation for being entrepreneur friendly. In May 2024, founder Girish Mathrubootham stepped down as CEO and transitioned to Executive Chairman. Dennis Woodside, who joined as President in 2022, took over as CEO. As of 2024, the firm reported a figure of 70%. [6] [7] [8]

What the firm says

Qiming Venture Partners describes itself as a top-tier venture capital firm with an outstanding reputation, noting that it has been widely recognized by investors from around the world for its exceptional investment performances. The firm states that it was founded in 2006 and currently manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since its establishment, the firm has invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. It reports having invested in over 580 fast-growing and innovative companies, including over 80 portfolio companies that have achieved unicorn or super unicorn status. The firm emphasizes that it is committed to finding great companies for the future and bringing long-term value to societies. Its investment team spends significant time researching industry trends, technology developments, and changes in consumer habits. The firm makes comprehensive contact with entrepreneurs to better grasp investment opportunities and assess risks through a deep understanding of business operations and scientific research data. A key component of its strategy is focus, aiming to have good insights and rich contacts for specific industries, truly understand invested projects, help after investment, and form an ecosystem within its portfolio companies. Qiming Venture Partners and its partners consistently rank among the leaders in the global venture capital industry across various prestigious lists. [3] [8] [11] [12]

What the press says

Press coverage highlights recent recognition and strategic shifts for Qiming Venture Partners. In 2026, Managing Partner Alex Zhou was named to the Forbes Midas List, a distinction reported by finance.yahoo.com. The firm’s financial scale has been noted across various years and sources. Wikipedia reported the firm at $3.2 Billion in 2021. By 2022, ionanalytics.com cited figures of USD 2.5bn and USD 600m. More recent reporting from ionanalytics.com in 2026 describes Qiming as making strategic and operational pivots for the next phase of China VC. The source notes that Qiming is in a very good place, with external strategy changes bearing early fruit and internal organisational adjustments having settled. The press also references the firm’s participation in market escalation, specifically noting that Qiming scaled Fund VI from USD 648m to USD 935m. [9] [10] [11]

Where the sources disagree

• The reported founding year of 2006 lacks independent verification, as it appears only on three non-primary hosts, meaning an LP cannot rely on this date as a confirmed historical fact. [6] [7] [8]
• The stated $9.5 billion in funds raised is not independently corroborated by primary sources or data publishers, appearing only on two non-primary hosts, so an LP should treat this figure as unverified rather than established. [3] [8]

Analysis

The $9.5 billion funds raised figure is the firm's own claim, repeated rather than independently reported. This means you are relying on the manager's self-reported data, which may not reflect audited or third-party verified totals. [3] [8]

The 2006 founding date is the firm's own claim, repeated rather than independently reported. This means the firm's stated history is not corroborated by primary sources or independent data publishers, so you should verify the actual inception date through legal documents or regulatory filings. [6] [7] [8]

Pros and cons for an LP weighing a commitment to this manager

Pros

• The manager has demonstrated significant capital raising capability, growing from a $550M fund in 2017 to managing $9.5 billion across eleven USD and seven RMB funds, indicating strong LP confidence and scale. [1] [3] [8]
• Qiming Venture Partners has achieved substantial portfolio success, with over 80 companies reaching unicorn or super-unicorn status, which signals a high probability of outsized returns for committed capital. [3]
• The firm’s recent strategic adjustments are bearing fruit, with Fund VI scaling from USD 648m to USD 935m, demonstrating an ability to adapt and raise larger checks in a competitive market. [10]
• Qiming Venture Partners maintains a top-tier reputation and is recognized as a leader in the global venture capital industry, which reduces counterparty risk and ensures access to high-quality deal flow. [8]
• The manager’s focus on early to growth-stage investments in high-growth sectors like AI, robotics, and healthcare positions the fund to capture structural market shifts, such as the predicted shortage in AI infrastructure over the next two years. [6] [7] [12]

Cons

• The firm’s strategy is heavily concentrated in the Technology and Healthcare sectors, meaning an LP’s returns are tied to the performance of these specific industries rather than a diversified global portfolio. [6] [7] [8]
• The firm’s investment thesis relies on the assumption that AI infrastructure will face structural shortages for the next two years; if this supply-demand dynamic shifts, the value of its AI-focused portfolio companies could be negatively impacted. [12]
• The firm’s strategy depends on the maturation and cost reduction of dexterous hands with tactile perception by 2027; failure of this technology to mature as predicted poses a risk to its robotics and AI investments. [12]